Abstract Number: 077 • 2020 Pediatric Rheumatology Symposium
Tubulointerstitial Nephritis and Uveitis (TINU): A Pediatric Case Series with Longitudinal Followup
Background/Purpose: Tubulointerstitial nephritis and uveitis (TINU) syndrome is an uncommon condition that is likely under-recognized. The ideal treatment of both renal and ophthalmologic disease activity…Abstract Number: 101 • 2020 Pediatric Rheumatology Symposium
Uveitis Treatment in the CARRA II Registry: Tumor Necrosis Factor-inhibitors and Beyond
Background/Purpose: Uveitis associated with JIA (JIA-U) is the most common extra-articular complication of JIA. As JIA-U is associated with significant risk of visual loss and…Abstract Number: 136 • 2020 Pediatric Rheumatology Symposium
Prevalence of Paradoxical Psoriasis After Exposure to Tumor Necrosis Factor Inhibitors (TNFi) in Children from a Single Tertiary Center
Background/Purpose: Paradoxical psoriasis after exposure to tumor necrosis factor inhibitors (TNFi) has been increasingly reported in the adult population. Systematic studies in pediatric population are…Abstract Number: 933 • 2019 ACR/ARP Annual Meeting
Tumor Necrosis Factor Inhibitors Slow Radiologic Progression in Patients with Ankylosing Spondylitis: 18-year Longitudinal Cohort Study
Background/Purpose: It is difficult to evaluate the role of TNF inhibitor therapy in slowing the radiologic progression in patients with ankylosing spondylitis (AS) because of…Abstract Number: 1518 • 2019 ACR/ARP Annual Meeting
Tumour Necrosis Factor Inhibitor Monotherapy versus Combination Therapy with Conventional Synthetic Disease-modifying Anti-rheumatic Drugs for the Treatment of Psoriatic Arthritis: A Combined Analysis of European Biologics Databases
Background/Purpose: A large proportion of psoriatic arthritis (PsA) patients are prescribed a tumour necrosis factor inhibitor (TNFi) in combination with methotrexate (MTX), however the value…Abstract Number: 935 • 2019 ACR/ARP Annual Meeting
Reduction of Anterior Uveitis Flares in Patients with Axial Spondyloarthritis Following 1 Year of Treatment with Certolizumab Pegol: 48-Week Interim Results from a 96-Week Open-Label Study
Background/Purpose: Acute anterior uveitis (AAU), inflammation of the anterior uveal tract, is the most common extraarticular manifestation in patients (pts) with axial spondyloarthritis (axSpA), reported…Abstract Number: 2009 • 2019 ACR/ARP Annual Meeting
Biomarkers Identified by Serum Inflammatory Profile Analysis to Predict Biologic Treatment Response in Rheumatoid Arthritis Patients
Background/Purpose: Biologic disease modifying antirheumatic drugs (b-DMARDs) have revolutionized the management of Rheumatoid Arthritis (RA). Despite this success, a high percentage of the patients undergoing…Abstract Number: 936 • 2019 ACR/ARP Annual Meeting
Earlier Treatment of Non-Radiographic Axial Spondyloarthritis with Certolizumab Pegol Results in Improved Clinical and Patient-Reported Outcomes
Background/Purpose: Patients (pts) with axial spondyloarthritis (axSpA) often experience delayed diagnosis, which can lead to treatment delay. However, there are indications that earlier treatment with…Abstract Number: 2112 • 2019 ACR/ARP Annual Meeting
Real Life Serious Infections in Patients with Chronic Inflammatory Arthritis on Treatment with TNF Inhibitors
Background/Purpose: To study frequency and associated factors for serious infections in patients with inflammatory arthritis treated with TNF inhibitorsMethods: All the medical records of the…Abstract Number: 938 • 2019 ACR/ARP Annual Meeting
TNF Inhibitors Reduce Spinal Radiographic Progression in Axial Spondyloarthritis by Mechanisms Associated with but Also Independent of Disease Activity
Background/Purpose: Recent observational data suggest that TNFi reduce spinal radiographic progression in radiographic axial spondyloarthritis (r-axSpA) mostly by inhibiting disease activity1. Yet, resolution on the…Abstract Number: 2117 • 2019 ACR/ARP Annual Meeting
Impact of Tapering Targeted Therapies (bDMARDs or Jakinibs) on the Risk of Adverse Events of Special Interest in Patients with Rheumatoid Arthritis or Spondyloarthritis: A Systematic Analysis of the Literature and Meta-analysis
Background/Purpose: A previous meta-analysis1 showed that tapering of bDMARDs does not increase the risk of relapse in rheumatoid arthritis (RA) patients with remission or low…Abstract Number: 29 • 2019 ACR/ARP Annual Meeting
Therapeutic Anti-TNF Biologic Agents Exhibit Functional Differences in Blocking TNF-induced Effects on Human Monocytes In Vitro
Background/Purpose: Therapeutic anti-TNF biologic agents can be distinct in their structure and/or in their binding to TNF. Whether these differences affect the functional properties of…Abstract Number: 988 • 2019 ACR/ARP Annual Meeting
Translational Imaging of Treatment Effects for a Novel Anti-TNF-Steroid Antibody Drug Conjugate in a Rat Model of Rheumatoid Arthritis
Background/Purpose: Rheumatoid arthritis (RA) is an inflammatory joint disease of autoimmune etiology. If insufficiently treated, RA leads to joint damage and irreversible disability. Although there…Abstract Number: 2273 • 2019 ACR/ARP Annual Meeting
Risk of Serious Infections in Offspring According to TNFi Subtypes
Background/Purpose: TNFi subtypes have differential placental transfer, with some reaching higher fetal than maternal blood levels. Thus, certain TNFi subtypes could cause immunosuppression in the offspring.…Abstract Number: 94 • 2019 ACR/ARP Annual Meeting
Tumor Necrosis Factor Receptor 2 Signaling Potentiates Proliferation and Suppressive Activities of Follicular Regulatory T Cells
Background/Purpose: Tumor Necrosis Factor (TNF) α is a multifunctional cytokine with pro-inflammatory and anti-inflammatory characteristics. Regulatory T cells (Treg) express a remarkably high level of…
- 1
- 2
- 3
- …
- 29
- Next Page »